Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial - Cortes, Jorge E.; Gambacorti-Passerini, Carlo; Deininger, Michael W.; Mauro, Michael J.; Chuah, Charles; Kim, Dong-Wook; Dyagil, Irina; Glushko, Nataliia; Milojkovic, Dragana; le Coutre, Philipp; Garcia-Gutierrez, Valentin; Reilly, Laurence; et al. (Journal of clinical oncology, 2018)
Keywords: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds - adverse effects; Aniline Compounds - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - genetics; Disease Progression; Female; Fusion Proteins, bcr-abl - genetics; Genetic Predisposition to Disease; Humans; Imatinib Mesylate - adverse effects; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Middle Aged; Nitriles - adverse effects; Nitriles - therapeutic use; ORIGINAL REPORTS; Phenotype; Philadelphia Chromosome; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Quinolines - adverse effects; Quinolines - therapeutic use; Time Factors; Treatment Outcome; Young Adult